EP2032991A1 - Protein-biochip zum differentiellen screenen von protein-protein-wechselwirkungen - Google Patents
Protein-biochip zum differentiellen screenen von protein-protein-wechselwirkungenInfo
- Publication number
- EP2032991A1 EP2032991A1 EP07785530A EP07785530A EP2032991A1 EP 2032991 A1 EP2032991 A1 EP 2032991A1 EP 07785530 A EP07785530 A EP 07785530A EP 07785530 A EP07785530 A EP 07785530A EP 2032991 A1 EP2032991 A1 EP 2032991A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- native form
- native
- arrangement
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 159
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 157
- 238000012216 screening Methods 0.000 title claims abstract description 16
- 238000000018 DNA microarray Methods 0.000 title claims description 12
- 230000004850 protein–protein interaction Effects 0.000 title description 5
- 239000011230 binding agent Substances 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000027455 binding Effects 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 25
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108010032595 Antibody Binding Sites Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 6
- 108091008324 binding proteins Proteins 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 108091005573 modified proteins Proteins 0.000 claims description 5
- 102000035118 modified proteins Human genes 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 108091005601 modified peptides Proteins 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 102000005720 Glutathione transferase Human genes 0.000 claims description 2
- 108010070675 Glutathione transferase Proteins 0.000 claims description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 241001195348 Nusa Species 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 102000028861 calmodulin binding Human genes 0.000 claims description 2
- 108091000084 calmodulin binding Proteins 0.000 claims description 2
- 239000005090 green fluorescent protein Substances 0.000 claims description 2
- 101150066555 lacZ gene Proteins 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 108060008226 thioredoxin Proteins 0.000 claims description 2
- 229940094937 thioredoxin Drugs 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 102100036407 Thioredoxin Human genes 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims 1
- 102000044466 Galectin-10 Human genes 0.000 description 5
- 101001051087 Homo sapiens Galectin-10 Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 102000023732 binding proteins Human genes 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
Definitions
- the present invention relates to an array of protein binders containing at least one protein binder presented in at least one native or natural form and at least one non-native and its use or methods for discriminating or screening different suitable protein binders which are the native or non-native form of protein binders detect.
- Protein biochips are gaining increasing industrial importance in analytics and diagnostics as well as in pharmaceutical development.
- expression vectors have sequences for so-called affinity epitopes or proteins, which on the one hand allow the specific detection of the recombinant fusion proteins by means of an antibody directed against the affinity epitope, on the other hand, the specific purification via affinity chromatography (IMAC) allows.
- affinity epitopes or proteins which on the one hand allow the specific detection of the recombinant fusion proteins by means of an antibody directed against the affinity epitope, on the other hand, the specific purification via affinity chromatography (IMAC) allows.
- the gene products of a cDNA expression library from human fetal brain tissue in the bacterial expression system in Escherichia coli high-density format were placed on a membrane and bodies were successfully screened with different anti '. It could be shown that the proportion of full-length proteins is at least 66%.
- the recombinant proteins of this library could be expressed and purified at high throughput (Braun P., Hu, Y., Shen, B., Halleck, A., Koundinya, M., Harlow, J. and La Baer, J.
- protein-antibody-presenting arrangements are described as protein biochips (LaI et al (2002)
- Antibody arrays An embryonic but growing technology, DDT, 7, 143-149; Kuznetsov et al. (2003), Antibody microarrays: An evaluation of production parameters, Proteomics, 3, 254-264).
- specificity of binding of various monoclonal antibodies such as anti-HSP90 ⁇ , anti-GAPDH or anti- ⁇ -tubulin could be analyzed on a protein microarray consisting of 96 human recombinantly expressed proteins by means of protein biochips (Lueking (1999)).
- recombinant proteins for example, therapeutic proteins usually have specific differences to the physiological or native homologs, be it for example in the folding, in the presence of auxiliary sequences so-called.
- Tags N- or. C-terminal alterations, post-translational modifications, e.g. Glycosylations, phosphorylations, acylations, alkylations, oxidations, etc., or in the presentation of a binding site leading to changes in the protein-protein interaction (protein to bind to a protein binder).
- the invention addresses the problem of enabling differential screening of protein binders to distinguish the native form from a non-native form, thereby selecting suitable native and non-native forms.
- the object is achieved in that an arrangement of protein binders containing at least one protein binder presented in at least one native form and at least one non-native form, the particular form having at least one recognition signal for binding one or more proteins, together with means for detecting the binding success.
- the binding success allows a statement about the suitability or differentiation of the non-native form compared to the native form of a protein binder.
- non-native proteins which are subject to, for example, any non-natural purification process or production method (such as a recombinant method) and its homogeneity, bioequivalence, batch uniformity, activity and Function should be determined in comparison to the native form of the protein.
- Such an inventive arrangement is suitable for differential screening or selection and selection of at least one native or non-native form.
- the recognition signal is preferably an epitope and / or paratope.
- the native form of a protein binder is one which corresponds to the protein binder of its function (eg immunoglobulins, therapeutic proteins, structural proteins, membrane proteins, etc.).
- the original function is ensured by the protein structure in its sequence, conformation or configuration (primary, secondary, tertiary, quaternary structure).
- the protein binder has an epitope (Paratop), which in its native form can be safely recognized by an antibody or a molecule similar in binding affinity and selectivity (antigen).
- the native form is one that can be obtained from a living organism (in vivo) or is known.
- the native form may be an accepted standardized form of a protein, for example, for a particular function. Such a function is not ultimately a diagnostic or physiological function of a protein.
- the non-native form of a protein binder is one in which, compared to the native protein binder, the function can be changed, even impaired or modified.
- the original function is not guaranteed by the modified or modified protein structure in its sequence, conformation or configuration or modification.
- the protein binder has an altered epitope (Paratop), which in its non-native form can not be recognized by an antibody or a binding affinity and selectivity-like molecule (antigen) compared to the native form.
- a non-native form of a protein binder is one wherein the protein binder has been produced synthetically or recombinantly, or the native protein binder has been physically or chemically denatured, and has differences in particular in conformation and configuration to the native form.
- the folding of the protein binder in its non-native form is decisive in comparison to the native form.
- the recognition signal e.g., epitope, paratope
- the recognition signal for a protein to be bound may be disturbed / abolished or misplaced so that the addressing of the protein to be bound is misdirected.
- the non-native form is the denatured form of a protein.
- this denatured form of a protein is compared to the non-denatured form (or: native form). It requires the production of denatured forms for example, denaturants (urea, acids, bases, SDS, guanidine hydrochloride, salt, etc.) or physical denaturation, eg high temperatures, ⁇ -rays, UV-rays, lasers etc.
- denaturants urea, acids, bases, SDS, guanidine hydrochloride, salt, etc.
- physical denaturation eg high temperatures, ⁇ -rays, UV-rays, lasers etc.
- the native form is a non-modified form and the non-native form is a modified form.
- the modified forms have opposite to the unmodified structural changes, e.g. not final removal of phosphates in phosphorylated proteins, removal of carbohydrates in glycolated
- Proteins, or removal of lip (o) iden in lip (o) idformaten proteins, or removal of post translational structures in the protein may be to chemically alter the native form chemically (e.g., phosphorylation, glycation, lip (o) idization,
- the modification may be that the native form (unmodified form) is ligated with another protein to a fusion protein (modified form).
- the native form (unmodified form) is modified such that the native form is cleaved into fragments. Be it e.g. by enzymatic or chemical or physical cleavage.
- the native form is, for example, a naturally occurring target or marker, in particular a biomarker, which is suitable for the diagnosis or therapy of diseases in humans and animals and comparatively investigated in comparison with a denatured (non-native) form or modified form should be.
- denatured or modified forms to be compared can be produced, for example, by a purification process or isolation process.
- the protein binder is an antigen (epitope) or antibody (paratope), in particular monoclonal or polyclonal antibody. Also preferred are protein binders that contain portions of an antibody, such as Fab or Fc fragments. In addition, Affibody® (Affibody, Sweden) is also included.
- protein binder in the sense of this invention means that a protein to be bound in the presence of a protein binder contacts it or binds to it or at least interacts with it
- the protein to be bound is addressed to the protein binder or the protein to be bound recognizes the protein binder or the protein binder has the potential to interact with a protein (eg, antigen (epitope) / antibody (paratope) interaction).
- Protein binders may be proteins, peptides, modified proteins / peptides, recombinant proteins / peptides, antibodies or a molecule or antigen similar in binding affinity and selectivity, or other proteins which may be represented on a protein biochip according to the invention.
- Suitable proteins to bind to a protein binder in the context of this invention may not be conclusive: proteins, peptides, modified proteins / peptides, recombinant proteins / peptides, antibodies or antigens, or other proteins, proteids.
- the proteins to be bound may be in purified form as well as mixed or even in a heterogeneous protein mixture such as a lysate or digest (e.g., microorganism or plant lysates, tissue lysate, mammalian cell lysate). This reflects the quality of the binder in complex mixtures such as those found in immunohistochemistry.
- a lysate or digest e.g., microorganism or plant lysates, tissue lysate, mammalian cell lysate.
- the invention relates to such an arrangement of one or more protein binders, wherein a first region has at least one native form of a protein binder and a second region has at least one non-native form of a protein binder Protein Binder and these areas form a unit, which unit is at least one protein to be bound, preferably at the same time under standardized conditions, accessible.
- the protein binder in the respective form, native or non-native may be represented in different amounts in the first and / or second region.
- the first and second regions may each comprise a total of protein binders, i. a sufficient number of different protein binders. These may also be in a non-native or native form. At least 96 to 25,000 (numerically) or more of different protein binders are preferred. Preferably, however, more than 2,500, more preferably 10,000 or more protein binders resulting, for example, from an expression library.
- the invention relates to such an arrangement of protein binders also a diagnostic device or a protein biochip or protein microarray.
- arrangement synonymously means “array” and insofar as this "array” is used to identify proteins to be bound to protein binders, this is to be understood as an “assay”.
- the arrangement is designed such that the protein binders represented on the arrangement are in the form of a grid. Further, such arrangements are preferred which allow a high density array of protein binders. Such high density arrangements are disclosed, for example, in WO 99/57311 and WO 99/57312.
- the protein binders may be fixed in the assembly on a solid support, spotted or immobilized.
- the protein binders are present as clones.
- Such clones can be obtained, for example, by means of a cDNA expression library according to the invention (Büssow et al., 1998 (supra)).
- expression libraries containing clones are obtained by means of expression vectors from an expressing cDNA library. These expression vectors preferably contain inducible
- Induction of expression may be e.g. by means of an inductor, such as e.g. IPTG.
- an inductor such as e.g. IPTG.
- Suitable expression vectors are described in Terpe et al. (Terpe T Appl Microbiol Biotechnol 2003 Jan; 60 (5): 523-33).
- Expression libraries are known to the person skilled in the art, and these can be prepared according to standard works, such as Sambrook et al., Molecular Cloning, Laboratory Handbook, 2nd edition (1989), CSH press, CoId Spring Harbor, New York Further preferred are expression libraries which are tissue-specific.
- expression libraries which can be obtained by exon trapping are also included in the invention, and instead of an expression library it is possible to speak synonymously of an expression library.
- Uniclone® library protein biochips or corresponding expression libraries which have no redundancy
- Uniclone® library protein biochips or corresponding expression libraries which have no redundancy
- WO 99/57311 and WO 99/57312 protein biochips or corresponding expression libraries which have no redundancy
- These preferred Uniclone libraries have a high content of non-defective, fully expressed proteins of a cDNA expression library.
- the clones may not be such as transformed bacteria, recombinant phage or transformed cells of mammals, insects, fungi, yeasts or plants.
- the protein binders in the particular form may be in the form of a fusion protein containing, for example, at least one affinity epitope or "tag".
- the tag may be one such as c-myc, His-tag, Arg-tag, FLAG, alkaline phosphatase, V5 tag, T7 tag or Strep tag, HAT tag, NusA, S-tag, SBP tag , Thioredoxin, DsbA, a fusion protein, preferably a cellulosic binding domain, green fluorescent protein, maltose binding protein, calmodulin binding protein, glutathione S-transferase or lacZ.
- solid support includes embodiments such as a filter, a membrane, a magnetic bead, a silicon wafer, glass, metal, a chip, a mass spectrometric target, or a matrix.
- PVDF polyvinyl styrene
- nitrocellulose polymethyl methacrylate
- nylon polymethyl methacrylate
- this corresponds to a grid having the size of a microtiter plate (96 wells, 384 wells or more), a silicon wafer, a chip, a mass spectrometric target or a matrix.
- the evaluation is carried out, for example, using commercially available image analysis software (GenePix Pro (Axon Laboratories), Aida (Raytest), ScanArray (Packard Bioscience).
- Fluorescent labeling, biotinization or radio-isotope labeling in a conventional manner is carried out for example by means of a microarray laser scanner.
- the invention relates to a method for the differential screening of suitable protein binders in non-native form, wherein the detection of a binding success of a protein to a protein binder in non-native form is sufficient. Corresponding protein binders in non-native form are selected.
- the invention therefore relates to a method for the differential screening or discrimination of protein binders which have at least one native form and at least one non-native form, the respective form having at least one recognition signal for binding one or more proteins
- the method according to the invention particularly advantageously allows a discrimination of such protein binders with an epitope, Paratop, whereby a comparative examination of the native form with the non-native form takes place. It is essential here whether the respective sequence of an epitope, paratope is relevant for the protein to be bound or whether non-epitope, non-paratope sequences of the non-native form are relevant.
- the invention relates to a method for identifying and characterizing protein binders which present at least one native form and at least one non-native form, the respective form having at least one recognition signal for binding one or more proteins, bringing the native form into contact and non-native native form with at least one binding protein and evidence of binding success.
- a binding success is present with positive detection of the binding protein to a recognition signal of the protein binder.
- both the native form and the non-native form of the protein binder from the protein to be bound has a binding success.
- the inventive method is carried out on the basis of the above-described embodiments, in particular arrangements, in particular the native form is a non-modified or non-denatured form and the non-native form to be compared is a denatured or modified form.
- the methods of the invention allow such non-native forms, which have a binding success to select safely.
- the methods of the invention are used to screen suitable epitopes / paratopes.
- the invention also relates to the use of an arrangement according to the invention for the differential screening of suitable protein binders for distinguishing the non-native form from the native form.
- differential screening allows the selection or discrimination of such protein binders in non-native form, which therefore have no or no homologous function with respect to protein-protein interactions.
- FIG. 1 shows the differential screening of the protein binder galectin 10 in native form (non-denatured) and non-native form (denatured (denaturing agent: urea)), presented with various antibodies to be bound. Based on the binding curves (signal intensities vs.
- Diaclone 503.18Hl recognizes the native form of galectin 10 worse than the other antibodies, and the denatured form of galectin 10 better.
- the antibody MOR Aby491.3 recognizes the native form of galectin 10 best, but the denatured form of galectin 10 is significantly worse than the other antibodies.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006027259A DE102006027259A1 (de) | 2006-06-09 | 2006-06-09 | Protein-Biochip zum differentiellen Screenen von Protein-Protein-Wechselwirkungen |
PCT/DE2007/001029 WO2007140768A1 (de) | 2006-06-09 | 2007-06-11 | Protein-biochip zum differentiellen screenen von protein-protein-wechselwirkungen |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2032991A1 true EP2032991A1 (de) | 2009-03-11 |
Family
ID=38562836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07785530A Ceased EP2032991A1 (de) | 2006-06-09 | 2007-06-11 | Protein-biochip zum differentiellen screenen von protein-protein-wechselwirkungen |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100331201A1 (de) |
EP (1) | EP2032991A1 (de) |
DE (1) | DE102006027259A1 (de) |
WO (1) | WO2007140768A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2437060A1 (de) * | 2010-10-01 | 2012-04-04 | Protagen AG | Markersequenzen für Multiple Sklerose und deren Verwendung |
SG188698A1 (en) * | 2011-09-09 | 2013-04-30 | Albena Samokovlisky Ph D | Improved glycosylation assay, glycoanalysis array and an assay system |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR231590A1 (es) * | 1981-04-29 | 1984-12-28 | Ciba Geigy Ag | Dispositivo de analisis inmunologico y procedimiento para obtenerlo |
CA2184195C (en) * | 1995-10-25 | 2002-04-16 | Andrew Pakula | Screening method for identifying ligands for target proteins |
DE10152677A1 (de) * | 2001-10-19 | 2003-05-08 | Aventis Behring Gmbh | Antikörper zum spezifischen Nachweis von pathogenen Prionen humanen Ursprungs und damit durchgeführten Nachweisverfahren |
DE102004056794B4 (de) * | 2004-11-24 | 2010-08-26 | Protagen Ag | Verwendung einer Anordnung und Verfahren zur Validierung von Bindern |
-
2006
- 2006-06-09 DE DE102006027259A patent/DE102006027259A1/de not_active Ceased
-
2007
- 2007-06-11 EP EP07785530A patent/EP2032991A1/de not_active Ceased
- 2007-06-11 WO PCT/DE2007/001029 patent/WO2007140768A1/de active Application Filing
- 2007-06-11 US US12/304,060 patent/US20100331201A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2007140768A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007140768A1 (de) | 2007-12-13 |
US20100331201A1 (en) | 2010-12-30 |
DE102006027259A1 (de) | 2007-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60211651T2 (de) | Proteom-analyseverfahren | |
EP2483690A1 (de) | Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung | |
WO2006056438A2 (de) | Protein-biochip zur validierung von bindern | |
WO1997044491A1 (en) | Methods of detection utilizing modified bacteriophage | |
DE102006015001A1 (de) | Verfahren zum Nachweis und/oder zur Anreicherung von Analytproteinen und/oder Analytpeptiden aus einer komplexen Proteinmischung | |
EP1330655B1 (de) | Verfahren zur analyse von proteinen | |
EP2255195A2 (de) | Markersequenzen für rheumatoide arthritis und deren verwendung | |
WO2007140768A1 (de) | Protein-biochip zum differentiellen screenen von protein-protein-wechselwirkungen | |
WO2010000874A2 (de) | Markersequenzen für prostataentzündungserkrankungen, prostatakarzinom und deren verwendung | |
DE69927668T2 (de) | Massenfingerabdrucken und seiner verwendung zur identifizierung von protein-affinitätsliganden | |
EP1147419B1 (de) | Nachweis von zellen mittels spezifischer zellwand-bindender domänen (cbd) von zellwand-bindenden proteinen | |
EP2745115B1 (de) | Neues verfahren zur diagnostik von hochaffinen bindern und markersequenzen | |
DE102008007422A1 (de) | Stratifizierung und Therapiesteuerung eines Patienten mittels Proteinbiochips | |
EP1133697B1 (de) | Verfahren zur modifikation und identifikation funktioneller stellen in proteinen | |
KR20230116497A (ko) | 상호작용체 분석용 키트 및 이를 이용한 상호작용체 분석법 | |
DE102007041657A1 (de) | Markersequenzen für Multiple Sklerose und deren Verwendung | |
DE102007028050A1 (de) | Hautchip | |
DE60211714T2 (de) | Isolierung membrangebundener ligandenspezifischer komplexe | |
EP1504267B1 (de) | Festphasenassisitierte spektroskopische und spektrometrische analyse komplexer biopolymergemische | |
DE102010042359A1 (de) | Markersequenzen für Multiple Sklerose und deren Verwendung | |
WO2004019967A1 (en) | Method for isolating subpopulations of proteins that engage in protein-protein interactions | |
US20060275821A1 (en) | Method for isolating subpopulations of proteins that engage in protein-protein interactions | |
DE102005011579B4 (de) | Affinitätsmarker zur Proteinreinigung, seine Herstellung und Verwendung sowie Verfahren zur Aufreinigung eines Proteins | |
DE10220804A1 (de) | Festphasenassistierte spektroskopische und spektrometrische Analyse komplexer Biopolymergermische | |
DE102007041654A1 (de) | Markersequenzen für juvenile idiopathische Arthritis und deren Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090825 |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20121023 |